Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Meglumine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 known ✓ | P25103 | 18/20 | 0.61 |
| ▸ | TACR3 | P29371 | 2/20 | 0.61 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.61 |
| ▸ | FPR1 | P21462 | 1/20 | 0.61 |
| ▸ | GPR183 | P32249 | 1/20 | 0.61 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.61 |
| ▸ | GPR65 | Q8IYL9 | 1/20 | 0.61 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.61 |
| ▸ | TACR2 | P21452 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20826783 | 0.91 | TACR1 (0.73) | TACR1TACR3NR3C1CYP3A4FPR1 | |
| Fosaprepitant SCHEMBL29358080 | 0.89 | TACR1 (0.61) | TACR1TACR3NR3C1CYP3A4FPR1 | |
| Fosaprepitant SCHEMBL21049946 | 0.89 | TACR1 (0.61) | TACR1TACR3NR3C1CYP3A4FPR1 | |
| SCHEMBL175836 | 0.83 | TACR1 (0.61) | TACR1TACR3NR3C1CYP3A4FPR1 | |
| Fosaprepitant SCHEMBL17837327 | 0.83 | TACR1 (0.59) | TACR1TACR3NR3C1CYP3A4FPR1 | |
| Fosaprepitant SCHEMBL22076807 | 0.83 | TACR1 (0.59) | TACR1TACR3NR3C1CYP3A4FPR1 | |
| Fosaprepitant SCHEMBL30861885 | 0.83 | TACR1 (0.59) | TACR1TACR3NR3C1CYP3A4FPR1 | |
| Fosaprepitant SCHEMBL156378 | 0.83 | TACR1 (0.59) | TACR1TACR3NR3C1CYP3A4FPR1 | |
| SCHEMBL11929279 | 0.81 | TACR1 (0.80) | TACR1TACR3NR3C1CYP3A4FPR1 | |
| SCHEMBL18388496 | 0.81 | TACR1 (0.79) | TACR1TACR3NR3C1CYP3A4FPR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120309726-A1 | COMBINATIONS COMPRISING ANTIMUSCARINIC AGENTS AND PDE4 INHIBITORS | GRAS ESCARDO JORDI (ES) | 2012-12-06 | — | — | US | disclosed |
| US-20080051378-A1 | Combinations Comprising Antimuscarinic Agents and Corticosteroids | LABORATORIOS ALMIRALL, S.A. (ES) | 2008-02-28 | — | — | US | disclosed |
| US-20060205702-A1 | Combinations comprising antimuscarinic agents and corticosteroids | LABORATORIOS ALMIRALL, S.A. (ES) | 2006-09-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120309726-A1 | COMBINATIONS COMPRISING ANTIMUSCARINIC AGENTS AND PDE4 INHIBITORS | CHRM3, CHRM4, PDE4A | TACR1 121/4885TACR3 125/4885NR3C1 1509/4885 |
| US-20080051378-A1 | Combinations Comprising Antimuscarinic Agents and Corticosteroids | CHRM3, CHRM4, CHRM2 | TACR1 115/4885TACR3 268/4885NR3C1 105/4885 |
| US-20060205702-A1 | Combinations comprising antimuscarinic agents and corticosteroids | CHRM3, CHRM2, CHRM1 | TACR1 67/4885TACR3 153/4885NR3C1 18/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.